Previous article
Using Artificial Intelligence in Screening Mammography
Nov 2024
Next article
Documenting US Citizenship Examination Exemption for Medically Qualified Refugees
STEPS
New Drug Reviews

Brexpiprazole (Rexulti) for the Treatment of Agitation Associated With Alzheimer Disease

Jennie B. Jarrett, PharmD, MMedEd, PhD
Alexander F. Infante, PharmD, BCPS

American Family Physician. 2024;110(5):537-538.

Author disclosure: No relevant financial relationships.

JENNIE B. JARRETT, PharmD, MMedEd, PhD, University of Illinois, Retzky College of Pharmacy, Chicago

ALEXANDER F. INFANTE, PharmD, BCPS, UIC College of Pharmacy, Chicago, Illinois

Address correspondence to Jennie B. Jarrett, PharmD, MMedEd, PhD, at jarrett8@uic.edu.

Author disclosure: No relevant financial relationships.

  1. 1.DailyMed. Drug label information. Rexulti—brexpiprazole tablet. Updated May 14, 2024. https://www.dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2d301358-6291-4ec1-bd87-37b4ad9bd850
  2. 2.Grossberg GT, Kohegyi E, Mergel V, et al. Efficacy and safety of brexpiprazole for the treatment of agitation in Alzheimer’s dementia: two 12-week, randomized, double-blind, placebo-controlled trials. Am J Geriatr Psychiatry. 2020;28(4):383-400.
  3. 3.Lee D, Slomkowski M, Hefting N, et al. Brexpiprazole for the treatment of agitation in Alzheimer dementia: a randomized clinical trial. JAMA Neurol. 2023;80(12):1307-1316.
  4. 4.Rabinowitz J, Davidson M, De Deyn PP, et al. Factor analysis of the Cohen-Mansfield Agitation Inventory in three large samples of nursing home patients with dementia and behavioral disturbance. Am J Geriatr Psychiatry. 2005;13(11):991-998.
  5. 5.Meunier J, Creel K, Loubert A, et al. Defining a clinically meaningful within-patient change threshold for the Cohen-Mansfield Agitation Inventory in Alzheimer’s dementia. Front Neurol. 2024;15:1379062.

STEPS new drug reviews cover Safety, Tolerability, Effectiveness, Price, and Simplicity. Each independent review is provided by authors who have no financial association with the drug manufacturer.

This series is coordinated by Allen F. Shaughnessy, PharmD, assistant medical editor.

A collection of STEPS published in AFP is available at https://www.aafp.org/afp/steps.

Previous article
Using Artificial Intelligence in Screening Mammography
Nov 2024
Next article
Documenting US Citizenship Examination Exemption for Medically Qualified Refugees

Current issue

May 2026

May 2026

Copyright © 2026 by the American Academy of Family Physicians.

This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. See permissions for copyright questions and/or permission requests.